EMEA-003239-PIP01-22
Key facts
| Active substance |
Dimeric protein comprised of two disulfide-linked monomers, each being a fully human fusion protein consisting of a modified extracellular domain of the human activin receptor type IIA fused to the fragment crystallizable domain of human IgG1 Fc including the hinge region, CH2 and CH3 domains (KER-050)
|
| Therapeutic area |
|
| Decision number |
P/0407/2022
|
| PIP number |
EMEA-003239-PIP01-22
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Keros Therapeutics, Inc.
E-mail: etreece@kerostx.com Tel: +1 (617)3146297 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|